Atralin™ Gel Provides Results You and Your Patients Can Embrace
Tretinoin Reinvented Tolerability Efficacy Results Prescribing Information
 

ATRALIN™ Gel Offers the Efficacy You Expect from a Tretinoin1

The charts below reflect the mean percent reduction in non-inflammatory, inflammatory, and total facial lesions achieved with ATRALIN™ (tretinoin) Gel 0.05% compared to vehicle.

 

Mean percent reduction of
facial lesions at Week 12

Chart1
Global Severity Score:
21%
Global Severity Score:
12%

Study design: 12-week, prospective, multi-center, randomized, controlled study of patients with mild-to-moderate acne vulgaris of the face (N=560). Success on a 6-point Global Severity Score was defined as a score of 0 (clear) or 1 (very mild).

 

 

Mean percent reduction of
facial lesions at Week 12

Chart2
Global Severity Score:
23%
Global Severity Score:
14%

Study design: 12-week, prospective, multi-center, randomized, controlled study of patients with mild-to-moderate acne vulgaris of the face (N=601). Success on a 6-point Global Severity Score was defined as a score of 0 (clear) or 1 (very mild) with at least 2 grades reduction from baseline.

 

Reference: 1. Data on file, CORIA Laboratories, Ltd.